Table 2.
Patient characteristics in the propensity score matched cohort.
| Variable | Surgery N=234 |
Non-surgery N=234 |
P |
|---|---|---|---|
| Age | 0.405 | ||
| <65 | 119 (50.9%) | 129 (55.1%) | |
| ≥65 | 115 (49.1%) | 105 (44.9%) | |
| Gender | 0.921 | ||
| Male | 159 (67.9%) | 161 (68.8%) | |
| Female | 75 (32.1%) | 73 (31.2%) | |
| Race | 0.483 | ||
| White | 135 (57.7%) | 151 (64.5%) | |
| Black | 54 (23.1%) | 47 (20.1%) | |
| American indian/Alska native | 3 (1.28%) | 1 (0.43%) | |
| Asian or Pacific Islander | 40 (17.1%) | 32 (13.7%) | |
| Unknown | 2 (0.85%) | 3 (1.28%) | |
| Marital status | 0.969 | ||
| Married | 139 (59.4%) | 139 (59.4%) | |
| Single | 46 (19.7%) | 46 (19.7%) | |
| Divorced/Widowed/Separated | 40 (17.1%) | 38 (16.2%) | |
| Unknown | 9 (3.85%) | 11 (4.70%) | |
| Year of diagnosis | 0.933 | ||
| 2010 | 32 (13.7%) | 26 (11.1%) | |
| 2011 | 23 (9.83%) | 22 (9.40%) | |
| 2012 | 27 (11.5%) | 34 (14.5%) | |
| 2013 | 23 (9.83%) | 24 (10.3%) | |
| 2014 | 22 (9.40%) | 21 (8.97%) | |
| 2015 | 24 (10.3%) | 24 (10.3%) | |
| 2016 | 21 (8.97%) | 21 (8.97%) | |
| 2017 | 24 (10.3%) | 20 (8.55%) | |
| 2018 | 22 (9.40%) | 30 (12.8%) | |
| 2019 | 16 (6.84%) | 12 (5.13%) | |
| Primary site | 0.967 | ||
| Gastric antrum | 50 (21.4%) | 49 (20.9%) | |
| Cardia and fundus of stomach | 68 (29.1%) | 68 (29.1%) | |
| Body of stomach | 18 (7.69%) | 21 (8.97%) | |
| Other sites | 98 (41.9%) | 96 (41.0%) | |
| Adenocarcinoma | 0.770 | ||
| YES | 152 (65.0%) | 156 (66.7%) | |
| NO | 82 (35.0%) | 78 (33.3%) | |
| T stage | 0.974 | ||
| T1 | 12 (5.13%) | 15 (6.41%) | |
| T2 | 14 (5.98%) | 12 (5.13%) | |
| T3 | 83 (35.5%) | 82 (35.0%) | |
| T4 | 99 (42.3%) | 99 (42.3%) | |
| Unknown | 26 (11.1%) | 26 (11.1%) | |
| N stage | 0.833 | ||
| N0 | 86 (36.8%) | 78 (33.3%) | |
| N1 | 71 (30.3%) | 69 (29.5%) | |
| N2 | 33 (14.1%) | 34 (14.5%) | |
| N3 | 28 (12.0%) | 36 (15.4%) | |
| Unknown | 16 (6.84%) | 17 (7.26%) | |
| Grade | 0.371 | ||
| I/II | 74 (31.6%) | 63 (26.9%) | |
| III/IV | 117 (50.0%) | 132 (56.4%) | |
| Unknown | 43 (18.4%) | 39 (16.7%) | |
| Radiation | 0.071 | ||
| No | 200 (85.5%) | 184 (78.6%) | |
| Yes | 34 (14.5%) | 50 (21.4%) | |
| Chemotherapy | 0.244 | ||
| No | 75 (32.1%) | 88 (37.6%) | |
| Yes | 159 (67.9%) | 146 (62.4%) | |
| Synchronous metastasis patterns | <0.001 | ||
| Only liver metastasis | 200 (85.5%) | 188 (80.3%) | |
| Liver combined with one other site metastasis | 23 (9.83%) | 20 (8.55%) | |
| Liver combined with two other sites metastasis | 1 (0.43%) | 2 (0.85%) | |
| Liver combined with three other sites metastasis | 0 (0.00%) | 16 (6.84%) | |
| Liver combined with unknown other metastasis | 10 (4.27%) | 8 (3.42%) |
Statistical significance was set at p<0.05. The bold values mean the significant difference between variables.